Insider Transactions in Q1 2025 at Clover Health Investments, Corp. (CLOV)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 18
2025
|
Brady Patrick Priest CEO of Home Care |
SELL
Payment of exercise price or tax liability
|
Direct |
38,560
-1.51%
|
$154,240
$4.08 P/Share
|
|
Jan 07
2025
|
Vivek Garipalli Director |
SELL
Payment of exercise price or tax liability
|
Direct |
1,670,965
-54.25%
|
$5,012,895
$3.6 P/Share
|
|
Jan 07
2025
|
Vivek Garipalli Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,670,965
+35.17%
|
-
|
|
Jan 07
2025
|
Jamie L. Reynoso CEO, Medicare Advantage |
SELL
Payment of exercise price or tax liability
|
Direct |
17,142
-0.52%
|
$51,426
$3.6 P/Share
|
|
Jan 07
2025
|
Karen Soares General Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
4,308
-0.31%
|
$12,924
$3.6 P/Share
|
|
Jan 06
2025
|
Carladenise Armbrister Edwards Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+11.41%
|
-
|
|
Jan 06
2025
|
Anna U Loengard Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+9.23%
|
-
|
|
Jan 06
2025
|
Thomas L Tran Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+37.72%
|
-
|
|
Jan 06
2025
|
William G Robinson Jr Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+10.52%
|
-
|
|
Jan 06
2025
|
Chelsea Clinton Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+9.19%
|
-
|
|
Jan 06
2025
|
Lee Shapiro Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+9.24%
|
-
|
|
Jan 06
2025
|
Demetrios L. Kouzoukas Director |
BUY
Grant, award, or other acquisition
|
Direct |
60,975
+10.38%
|
-
|
|
Jan 03
2025
|
Jamie L. Reynoso CEO, Medicare Advantage |
SELL
Payment of exercise price or tax liability
|
Direct |
8,149
-0.24%
|
$24,447
$3.29 P/Share
|
|
Jan 01
2025
|
Andrew Toy Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
278,765
-2.4%
|
$836,295
$3.15 P/Share
|